



www.genfit.com

**GENFIT: TRANSFER TO THE EURONEXT PARIS
REGULATED MARKET – COMPARTMENT B – ON
APRIL 17, 2014**

Lille (France), Boston (Massachusetts, Etats-Unis), April 15, 2014 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces that it has obtained the **visa n°14-148 from the AMF** (Autorité des Marchés Financiers - French stock exchange authority) for the Prospectus issued in connection with the direct listing of GENFIT shares on the Euronext Paris regulated market, compartment B. GENFIT shares have been listed on the Alternext market of Euronext Paris since December 2006.

The delisting of GENFIT shares from Alternext Paris will take place on April 16, 2014, after the end of the trading session.

Trading of GENFIT shares on the Euronext Paris regulated market will start on April 17, 2014.

Share codes

Name: GENFIT

ISIN Code: FR0004163111 – Trading symbol: GNFT

ICB code: 4573 Biotechnology

Trading market: Euronext Paris, Compartment B

As of April 14 2014 after the end of the trading session, GENFIT had a market capitalization of €519 million, making it the most valuable company on Alternext.

Over the year 2013, average daily exchanges amounted to 542,621 shares, resulting in the highest liquidity on Alternext.

In addition, over the past 12 months, the performance of GENFIT shares is +259 %.

Jean-François Mouney, Chairman and CEO of GENFIT, declared: *«This trading transfer to Compartment B of NYSE Euronext Paris will improve the visibility of GENFIT shares thanks to its inclusion in numerous benchmark indexes. Moreover, this new trading group should facilitate the capital strengthening operations necessary to accelerate the Company's development in 2014, since certain investors favor the Euronext regulated market ».*

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Access to the Prospectus

Copies of the approved prospectus are available free of charge from GENFIT SA, as well as on the Internet websites of GENFIT (www.genfit.com) and the AMF (www.amf-france.org).

Risk factors

Investors are reminded of the risks described in Chapter 4 « Risk factors » of the first part, and in Chapter 2 of the second part of the prospectus approved by the AMF under visa n°14-148 as of April 14, 2014.

Contacts:

GENFIT

Jean-François Mouney, CEO & Chairman of the Management Board
Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian
Ph. +331 7544 8740 / +336 8788 4726 – barabian@milestones.fr